Journal of Chemotherapy最新文献

{"title":"The crucial relationship between vancomycin minimum inhibitory concentration and therapeutic efficacy against methicillin-resistant coagulase-negative staphylococci.","authors":"Yusuke Niinuma, Keisuke Kagami, Mitsuru Sugawara, Yoh Takekuma","doi":"10.1080/1120009X.2024.2394326","DOIUrl":"10.1080/1120009X.2024.2394326","url":null,"abstract":"<p><p>The area under the curve (AUC)/minimum inhibitory concentration (MIC) ratio was used as an indicator of the clinical efficacy of vancomycin. However, the target AUC/MIC has not been set for methicillin-resistant coagulase-negative staphylococci (MR-CNS), and the effectiveness of vancomycin in strains with high MIC is unknown. Therefore, we aimed to investigate the relationship between the vancomycin MIC and therapeutic efficacy in patients with MR-CNS bacteremia. The primary outcome was the difference in treatment failure rate when the MR-CNS vancomycin MIC was 1 or 2 µg/mL. The treatment failure rate did not significantly differ between the two groups (MIC 1 vs. MIC 2: 27.0% vs. 31.0%; <i>p</i> = 0.779). As a result of multivariate analysis, AUC/MIC_0-24 h ≤230 was extracted as risk factor for treatment failure, suggesting the importance of a sufficient initial loading dose and early blood concentration monitoring to increase AUC/MIC_0-24 h for successful treatment.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"326-333"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of synthetic lethality-associated subtypes and construction of risk model to predict breast cancer prognosis and immune characteristics.","authors":"Jianhong Tang, Weihong Chen, Weibao Zou, Shujuan Cao","doi":"10.1080/1120009X.2025.2512263","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2512263","url":null,"abstract":"<p><p>Synthetic lethality has emerged as a pivotal concept in cancer therapy, offering novel and promising strategies for treatment. In this study, we identified molecular subtypes associated with synthetic lethality in breast cancer and developed a prognostic signature based on synthetic lethality-related genes. Using the TCGA cohort, we screened differentially expressed synthetic lethal genes (DESLGs) and stratified patients into two distinct molecular subtypes based on their expression patterns. Immune profiling and clinical survival analyses revealed significant differences between these subtypes. A six-gene prognostic risk model was constructed using univariate and multivariate Cox regression analyses combined with LASSO regression, and its robustness was validated in independent GEO datasets. Independent prognostic analyses integrating clinical and pathological features were performed, followed by the construction of a nomogram to improve clinical applicability. The immune microenvironment was characterized using ssGSEA, ESTIMATE, and CIBERSORT algorithms, revealing a lower level of immune infiltration and distinct immune checkpoint expression in the high-risk group. In addition, patients in the high-risk group exhibited worse survival outcomes, higher tumor mutation burden, and increased resistance to several therapeutic agents. RT-qPCR analysis confirmed the differential expression of signature genes between breast cancer and normal mammary epithelial cells. These findings suggest that the synthetic lethality-based molecular subtypes and prognostic model offer reliable tools for evaluating clinical outcomes and guiding individualized therapy in breast cancer patients.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-22"},"PeriodicalIF":1.9,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erythema multiforme as a rare skin manifestation during pembrolizumab treatment: a case report and literature review.","authors":"G Silvi, E Rosi, I Scandagli, A Di Cesare, F Prignano","doi":"10.1080/1120009X.2025.2512264","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2512264","url":null,"abstract":"<p><p>We report the case of a 77-year-old man with recurrent oral squamous cell carcinoma who developed erythema multiforme (EM) following his third dose of pembrolizumab (PBZ). The patient presented with a widespread skin rash characterized by erythematous papules and plaques that evolved into targetoid lesions, with no mucosal involvement or systemic symptoms. The treatment with a tapering dose of prednisolone resolved the rash without interrupting PBZ therapy. The report reviews the existing literature on PBZ-induced EM as a rare cutaneous toxicity associated with immune-checkpoint inhibitors (ICIs). Prompt recognition and appropriate management of EM are crucial. The discussion emphasizes the importance of distinguishing it from more severe conditions such as toxic epidermal necrolysis or Stevens-Johnson syndrome. Decisions regarding the continuation of PBZ therapy should be made collaboratively by dermatologists and oncologists, considering the patient's overall health and cancer treatment plan.Key PointsImmune-checkpoint inhibitors like pembrolizumab have revolutionized cancer treatment, though skin toxicities can complicate therapy.EM is a rare side effect of pembrolizumab, occurring in only 0.1% of patients, usually without affecting mucous membranes.Cases of pembrolizumab-induced EM vary in severity but generally respond well to corticosteroids.Quick identification of EM is essential, and treatment continuation should be carefully considered based on cancer type and severity.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-5"},"PeriodicalIF":1.9,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of pembrolizumab in patients with chemotherapy-resistant gestational trophoblastic neoplasia, a case report.","authors":"Sercan Ön","doi":"10.1080/1120009X.2025.2512262","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2512262","url":null,"abstract":"<p><p>Gestational trophoblastic neoplasia (GTN) is a rare malignancy that can develop following a hydatidiform mole or a non-molar pregnancy and often presents with metastasis. Although conventional chemotherapy achieves remission in over 90% of metastatic cases some patients develop resistance. I report a 36-year-old woman with metastatic GTN after prolonged uterin bleeding and elevated β-hCG levels. Despite multiple chemotherapy regimens, including cisplatin/etoposide and EMA-CO, the patient did not achieve remission. After the failure of conventional chemotherapy, pembrolizumab, an immune checkpoint inhibitor, was introduced. This treatment resulted in a rapid decrease in β-hCG levels and a complete biochemical response. The treatment was well tolerated, only minor immune-related adverse events. After eight cycles of pembrolizumab, she remained in remission for one year. This case highlights the potential role of immunotherapy in managing chemoresistant metastatic GTN and underscores the need for further studies to establish its effectiveness in such situations.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-4"},"PeriodicalIF":1.9,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cinobufagin regulates the microRNA-149-3p/AFF4 axis to affect the proliferation and apoptosis of cisplatin-resistant ovarian cancer cells.","authors":"Yunfei Liu, Taoli Chen, Yanpeng Wang, Yuanyuan Gao, Ning Xie, Wanping Xia, Qichuan Wang","doi":"10.1080/1120009X.2025.2508614","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2508614","url":null,"abstract":"<p><p>Although cinobufagin has been demonstrated to inhibit the growth of various malignant tumors, its functional role in ovarian cancer remains unclear. In light of this, the present study aims to thoroughly investigate the effects of cinobufagin on ovarian cancer progression and elucidate its underlying molecular mechanisms, thereby providing novel insights into future therapeutic strategies. A2780/DDP, a cisplatin-resistant cell line for ovarian cancer, was treated with gradient doses of cinobufagin. The microRNA-149-3p and AFF4 binding sites were predicted by bioinformatics. In cisplatin-resistant ovarian cancer cells, microRNA-149-3p and AFF4 expression were detected using qRT-PCR, and the binding association between microRNA-149-3p and AFF4 was confirmed by dual-luciferase and RIP assays. Cell viability was assessed using the CCK-8 test, cell proliferation was identified using the EdU assay and colony formation, and cell apoptosis was identified using flow cytometry. The results showed that cinobufagin inhibited the proliferation and promoted apoptosis of cisplatin-resistant ovarian cancer cells. microRNA-149-3p was highly expressed in cisplatin-resistant ovarian cancer cells, while AFF4 was lowly expressed in these cells. Overexpression of microRNA-149-3p promoted the proliferation and inhibited the apoptosis of cisplatin-resistant ovarian cancer cells, which was reversed by the addition of cinobufagin. Overexpression of AFF4 suppressed proliferation and promoted apoptosis of cisplatin-resistant ovarian cancer cells. MicroRNA-149-3p repressed AFF4 expression, and partial attenuation of the effects of AFF4 overexpression on cell phenotype was observed when microRNA-149-3p was overexpressed. In conclusion,cinobufagin regulated microRNA-149-3p/AFF4 axis to inhibit proliferation of ovarian cancer cells and promote cell apoptosis. Targeting the microRNA-149-3p/AFF4 axis with cinobufagin could represent a novel therapeutic strategy for ovarian cancer.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PqsR-specific quorum sensing inhibitors targeting <i>Pseudomonas aeruginosa</i>: current advances and future directions.","authors":"Mandsaurwala Aziz, Kafil Ahmed, Vinothkannan Ravichandran","doi":"10.1080/1120009X.2025.2510093","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2510093","url":null,"abstract":"<p><p>The emergence of multidrug-resistant (MDR) Pseudomonas aeruginosa is driven by diverse resistance mechanisms, including quorum sensing (QS) and biofilm formation. QS regulates virulence, antibiotic tolerance, efflux pumps, and biofilm development, enhancing the pathogen's adaptability. Among QS systems, the Pseudomonas quinolone signal regulator (PqsR) plays a central role in controlling virulence and biofilm-associated genes. This review critically examines the PqsR-regulated network and highlights the potential of PqsR inhibitors to reduce pathogenicity. Disrupting QS instead of targeting bacterial viability can enhance antibiotic efficacy, making this combinatorial approach a promising strategy to combat MDR <i>P. aeruginosa</i>.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-18"},"PeriodicalIF":1.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Docetaxel associated myositis.","authors":"Nadide Demırel, Metin Demır","doi":"10.1080/1120009X.2025.2505806","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2505806","url":null,"abstract":"<p><strong>Introducti̇on: </strong>Docetaxel is a microtubule inhibitor in the taxane group and it is a semisynthetic analogue of paclitaxel. It binds to β-tubulin subunits with high affinity, preventing the depolymerization of microtubules during metaphase. Myalgia has been frequently described as a docetaxel-related side effect. However, myositis is a rare side effect of docetaxel.</p><p><strong>Case report: </strong>A 64-year-old female patient with a right breast mass was diagnosed with invasive breast cancer. The tumor was 100% and 60% positive for estrogen and progesterone receptor, respectively and human epidermal growth factor receptor 2 (HER-2) was positive. There was not any distant metastasis in screening. It was clinically staged as T4N0M0 (stage 3B). Treatment was started with neoadjuvant chemotherapy (CT) as docetaxel plus trastuzumab (TR) plus pertuzumab. The patient applied to the outpatient clinic with muscle pain and weakness which started a few days after the second CT cycle.</p><p><strong>Management & outcome: </strong>The neurological physical exam was normal except that the muscle strength was 1/5 in the lower extremities with tense swelling. Joint pain or skin lesions were absent. Laboratory results revealed creatine kinase (CK) 4389 U/L. The patient was hospitalized with the diagnosis of myositis/myopathy due to these findings. Autoimmune markers were in normal range. The lower extremity magnetic resonance imaging (MRI) showed intense edema. The patient underwent a muscle biopsy. These findings were compatible with drug-associated necrotizing myopathy.</p><p><strong>Di̇scussi̇on: </strong>Docetaxel-related myositis is a rare complication and clinicians should be aware of this adverse event in patients with suspicious symptoms and with comorbidities.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NCAPG2 promotes the proliferation, metastasis and resistance to nab-paclitaxel in gastric adenocarcinoma cells.","authors":"Jia Xu, Xiaoyuan Liu, Zebo Huang, Ying Zhang, Xia Li, Dongyan Cai","doi":"10.1080/1120009X.2025.2498230","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2498230","url":null,"abstract":"<p><p>Gastric adenocarcinoma is one of the most common cancers in the world. The purpose of this study was to investigate the role of non-smooth muscle cell aggregation protein II complex G2 subunit (NCAPG2) in gastric cancer cells. Cell growth, proliferation, migration, invasion and albumin-bound paclitaxel resistance were detected by cell counting kit-8, flow cytometry, Transwell chamber and nude mouse xenograft model. Western blot was used to detect the expression of NCAPG2, STAT3 and NF-κB signaling pathways. The expression of NCAPG2 was significantly up-regulated in gastric adenocarcinoma cells. Knockdown of NCAPG2 inhibited cell proliferation, migration and invasion, and inhibited tumor growth. In addition, knockdown of NCAPG2 reduced the resistance of gastric adenocarcinoma cells to albumin-bound paclitaxel and down-regulated STAT3 and NF-κB signaling pathways. In summary, NCAPG2 plays an important role in the malignant progression of gastric adenocarcinoma and is involved in the resistance to albumin-bound paclitaxel.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.","authors":"Chia-Yu Kuo, Tzu-Wen Wang, Ann-Shung Lieu, Chih-Jen Yang","doi":"10.1080/1120009X.2025.2503052","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2503052","url":null,"abstract":"<p><p>Mutations in the <i>KRAS</i> gene are the most common gain-of-function mutations found in lung adenocarcinomas. The most prevalent mutation, <i>KRAS G12C</i>, occurs in 13% of lung adenocarcinomas. Sotorasib is an irreversible small molecule inhibitor that targets <i>KRAS G12C</i>. Previous studies have shown that treatment with sotorasib leads to the regression of <i>KRAS G12C</i>-mutated tumours. However, <i>KRAS G12C</i> often occurs alongside other mutations, such as <i>TP53</i>, <i>STK11</i> and <i>KEAP1</i>, which are associated with poor prognosis in advanced NSCLC when treated with sotorasib monotherapy. We present a case of metastatic NSCLC with <i>KRAS G12C</i>, <i>TP53</i> and <i>STK11</i> mutations that did not respond to sotorasib monotherapy. The patient received combination therapy with sotorasib and docetaxel, which resulted in remarkable efficacy. This case supports further investigation of sotorasib in combination with chemotherapy for treating <i>KRAS G12C</i>-mutated NSCLC with co-mutations.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-5"},"PeriodicalIF":1.9,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience.","authors":"Jamshid Hamdard, Ahmet Bilici, Abdullah Sakin, Seda Kahraman, Ayse Irem Yasin, Ender Kalaci, Ivo Gokmen, Ozgur Acikgoz, Yasin Kutlu, Mehmet Ali Nahit Sendur, Omer Fatih Olmez, Mesut Seker","doi":"10.1080/1120009X.2024.2358458","DOIUrl":"10.1080/1120009X.2024.2358458","url":null,"abstract":"<p><p>We evaluated the incidence, clinicopathological features, prognostic factors, progression-free survival (PFS) and overall survival (OS) of patients with gastric cancer and bone metastases. The medical records of 110 patients with bone metastases were retrospectively analyzed. In our study, the incidence of bone metastases was 3.2%. The median patient age was 60 years. A total of 68 (61.8%) patients exhibited synchronous metastases, and 42 (38.2%) patients developed metachronous metastases. Alkaline phosphatase (ALP) levels were high in 54 (49%) patients. At the median follow-up time of 9.8 months, median PFS and OS times were 4.7 and 6.3 months, respectively. The median interval from the diagnosis to bone metastases was 9.3 months. Univariate analysis showed that Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥2, stage at diagnosis, time of metastases, number of metastases, presence of extraskeletal metastases, use of zoledronic acid treatment, palliative chemotherapy post-bone metastases and radiotherapy to bone metastases were significant prognostic indicators for PFS. Additionally, ECOG PS ≥2, stage at diagnosis, time of metastases, number of metastases, presence of extraskeletal metastases, zoledronic acid treatment, palliative chemotherapy post-bone metastases, and radiotherapy to bone metastases significantly influenced OS. Moreover, in multivariate analysis, ECOG PS, time of metastases, presence of extra-bone metastases, and the use of palliative chemotherapy after bone metastases were found to be independent prognostic factors for PFS. Moreover, ECOG PS, time of metastases, and use of palliative chemotherapy after bone metastases were significantly independent prognostic indicators for OS. Our findings show that the presence of synchronous metastases, use of palliative chemotherapy, use of zoledronic acid after bone metastases, and ALP level within the normal range were significantly associated with prolonged OS in gastric cancer patients with bone metastases.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"268-277"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}